Title: Scientist and Researcher
Company: SanRx
Location: San Diego, California, United States
Phillip Moheno, scientist and researcher at SanRx, has been recognized by Marquis Who’s Who Top Scientists for dedication, achievements, and leadership in scientific research.
Dr. Moheno’s professional journey, spanning over four decades, is characterized by a profound commitment to scientific research and innovation. He laid the groundwork for his career with a Ph.D. in Education from the University of California, Santa Barbara, in 1985, building upon his earlier academic achievements, including a Candidate of Philosophy in biochemistry from the University of California, Los Angeles in 1976, and a Bachelor of Science in biochemistry from UCLA in 1974.
Throughout his career, Dr. Moheno has made significant contributions to the fields of biochemistry, cancer research, and pharmaceuticals. He currently serves as a scientist and researcher, operating independently since 2019. Previously, he held leadership positions at SanRx Pharmaceuticals, Inc., where he served as president and chief scientist from 2012 to 2018, and as acting president and chief scientist from 2004 to 2011. He has also shared his expertise as an adjunct professor at California State University from 2009 to 2016, and as a principal investigator at San Diego Research from 1996 to 2004. Earlier in his career, he served as an Assistant Professor at San Diego State University.
Dr. Moheno’s professional accomplishments extend beyond academia, with numerous patents and pending patents on drugs and nutraceuticals to his credit. He is a prolific author, having co-authored several influential publications in prestigious scientific journals. Notable among these is his co-authorship of “Immunopterin: A prospective therapy and preventative to fight COVID-19?” in Pteridines, which garnered widespread attention in 2022. Reflecting on his career highlights, he cites his pivotal role in the development of ImmunoPterin as a seminal achievement. This groundbreaking therapeutic agent holds promise for combating a range of diseases, including cancer, tuberculosis, hepatitis B, type 2 diabetes, colds, cases of flu, and COVID-19. Looking ahead, Dr. Moheno remains committed to advancing scientific knowledge and pursuing groundbreaking research.
Contact Dr. Moheno:
